[Molecular pathogenesis of heart failure].
Maier
L S
LS
Institut: Abt. Kardiologie and Pneumologie/Herzzentrum, Georg-August-Universität Göttingen. lmaier@med.uni-goettingen.de
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D002118:Calcium / Q000378:metabolism; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology*; D002302:Cardiac Output / Q000187:drug effects / Q000502:physiology; D006332:Cardiomegaly / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology; D004195:Disease Models, Animal; D004562:Electrocardiography; D006333:Heart Failure / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology*; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D044140:Receptor, Angiotensin, Type 1 / Q000502:physiology*; D015996:Survival Rate
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D044140:Receptor, Angiotensin, Type 1; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D002118:Calcium